- The Withings ScanWatch has received FDA clearance for atrial fibrillation detection through ECG.
- The FDA also granted clearance to the device for measuring users’ SpO2 levels.
- Shoppers will be able to grab a ScanWatch as soon as early November for $279.
The Withings ScanWatch is now the first wearable to earn FDA clearance for atrial fibrillation detection and SpO2 measurement from the wrist. This feat makes it the most medically advanced hybrid smartwatch on the market. While the device and its ECG monitor have previously received CE medical certification in Europe, the company was eager to face the thorough scrutiny of the FDA and is now excited to bring the watch to North American markets next month.
Read further: Withings ScanWatch review